Abstract Details
|
Zachary Grunwald
(Yale School of Medicine)
PRESENTER |
No disclosure on file |
| Sebastian Urday, MD (Massachusetts General Hospital, Brigham, Harvard) | No disclosure on file |
| Lauren A. Beslow, MD | Dr. Beslow has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various . The institution of Dr. Beslow has received research support from NIH. Dr. Beslow has received publishing royalties from a publication relating to health care. |
| No disclosure on file | |
| No disclosure on file | |
| Steven M. Greenberg, MD, PhD, FAAN | Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care. |
| Joshua Goldstein (Massachusetts General Hospital) | Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrazeneca. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Joshua Goldstein has stock in NControl. Joshua Goldstein has stock in Cayuga. The institution of Joshua Goldstein has received research support from Pfizer. The institution of Joshua Goldstein has received research support from Takeda. |
| No disclosure on file | |
| No disclosure on file | |
| Jonathan Rosand, MD (Massachusetts General Hospital) | Dr. Rosand has received personal compensation for serving as an employee of Massachusetts General Hospital. Dr. Rosand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Rosand has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for National Football League. The institution of Dr. Rosand has received research support from NIH. The institution of Dr. Rosand has received research support from American Heart Association. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as a Peer reviewer with National Institutes of Health. Dr. Rosand has a non-compensated relationship as a Trustee with Columbia University that is relevant to AAN interests or activities. |
| W. T. Kimberly, MD, PhD (Massachusetts General Hospital) | Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hyperfine Inc.. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from Biogen. The institution of Dr. Kimberly has received research support from NControl Therapeutics. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from American Heart Association. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care. |
| Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) | Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care. |